Herzliya, Israel

Elisheva Fabrikant

This inventor holds 9 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: West Pharma. Services Il, Ltd.. Active years: 2019-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elisheva Fabrikant. Retrieved from https://idiyas.com/inventor/elisheva-fabrikant

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Elisheva Fabrikant

Introduction: Elisheva Fabrikant is a pioneering inventor based in Herzliya, Israel, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Elisheva Fabrikant holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing her commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Elisheva Fabrikant has worked with top research institutions and leading tech companies to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout her career, Elisheva Fabrikant has collaborated with renowned scientists, engineers, and inventors from around the world, fostering a culture of innovation and knowledge-sharing.

Conclusion: Elisheva Fabrikant's passion for innovation and her relentless pursuit of technological excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…